Vaccine Advisory Panels Delay Decisions on Hepatitis B and COVID Shots, Raising Concerns
TL;DR
A U.S. federal vaccine advisory panel is debating delaying the hepatitis B vaccine for newborns, which could risk a resurgence of the disease, despite longstanding public health success. The delay is being considered for babies born to hepatitis B-negative mothers, but experts warn it could lead to more cases of chronic liver disease. The panel also discussed separating the MMRV vaccine doses, which has caused controversy and confusion about vaccination practices. The decisions reflect ongoing debates about vaccine safety, trust, and public health policy.
- Key federal vaccine panel debates delay to newborn hepatitis B shot, risking resurgence statnews.com
- CDC advisers vote to recommend against combo vaccine for young kids, delay vote on newborn hepatitis B shot CNN
- CDC advisers vote to change guidance on MMRV vaccines NPR
- RFK Jr.’s Vaccine Committee to Vote on Hepatitis B and Covid Shots The New York Times
- RFK Jr. vaccine advisers to consider coronavirus shot recommendations The Washington Post
Want the full story? Read the original reporting
Read on statnews.com